186 related articles for article (PubMed ID: 11695562)
1. The Tg.AC (v-Ha-ras) transgenic mouse: nature of the model.
Tennant RW; Stasiewicz S; Eastin WC; Mennear JH; Spalding JW
Toxicol Pathol; 2001; 29 Suppl():51-9. PubMed ID: 11695562
[TBL] [Abstract][Full Text] [Related]
2. Tg.AC genetically altered mouse: assay working group overview of available data.
Eastin WC; Mennear JH; Tennant RW; Stoll RE; Branstetter DG; Bucher JR; McCullough B; Binder RL; Spalding JW; Mahler JF
Toxicol Pathol; 2001; 29 Suppl():60-80. PubMed ID: 11695563
[TBL] [Abstract][Full Text] [Related]
3. Statistical analysis of skin tumor data from Tg.AC mouse bioassays.
Dunson DB; Haseman JK; van Birgelen AP; Stasiewicz S; Tennant RW
Toxicol Sci; 2000 Jun; 55(2):293-302. PubMed ID: 10828260
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the Tg.AC transgenic mouse assay for testing the human carcinogenic potential of pharmaceuticals--practical pointers, mechanistic clues, and new questions.
Sistare FD; Thompson KL; Honchel R; DeGeorge J
Int J Toxicol; 2002; 21(1):65-79. PubMed ID: 11936901
[TBL] [Abstract][Full Text] [Related]
5. Decreases in phorbol ester-induced papilloma development in v-Ha-ras transgenic TG.AC mice during reduced gene dosage of bcl-2.
Trempus CS; Haseman JK; Tennant RW
Mol Carcinog; 1997 Sep; 20(1):68-77. PubMed ID: 9328437
[TBL] [Abstract][Full Text] [Related]
6. Development of a transgenic mouse model for carcinogenesis bioassays: evaluation of chemically induced skin tumors in Tg.AC mice.
Spalding JW; French JE; Tice RR; Furedi-Machacek M; Haseman JK; Tennant RW
Toxicol Sci; 1999 Jun; 49(2):241-54. PubMed ID: 10416269
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Tg.AC assay: specificity testing with three noncarcinogenic pharmaceuticals that induce selected stress gene promoters in vitro and the inhibitory effects of solvent components.
Thompson KL; Rosenzweig BA; Weaver JL; Zhang J; Lin KK; Sistare FD
Toxicol Sci; 2003 Aug; 74(2):271-8. PubMed ID: 12773758
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of SEPA 0009-induced tumorigenesis in v-rasHa transgenic Tg.AC mice.
Fuhrman J; Shafer L; Repertinger S; Chan T; Hansen LA
Toxicol Pathol; 2005; 33(6):623-30. PubMed ID: 16176921
[TBL] [Abstract][Full Text] [Related]
9. The Tg.AC mouse model passes test by failing to respond.
Cannon RE
Toxicol Sci; 2003 Aug; 74(2):233-4. PubMed ID: 12892072
[No Abstract] [Full Text] [Related]
10. Association of tumor development with increased cellular proliferation and transgene overexpression, but not c-Ha-ras mutations, in v-Ha-ras transgenic Tg.AC mice.
Hansen LA; Trempus CS; Mahler JF; Tennant RW
Carcinogenesis; 1996 Sep; 17(9):1825-33. PubMed ID: 8824502
[TBL] [Abstract][Full Text] [Related]
11. Genetic alterations cooperate with v-Ha-ras to accelerate multistage carcinogenesis in TG.AC transgenic mouse skin.
Owens DM; Spalding JW; Tennant RW; Smart RC
Cancer Res; 1995 Jul; 55(14):3171-8. PubMed ID: 7606738
[TBL] [Abstract][Full Text] [Related]
12. Oral and dermal exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induces cutaneous papillomas and squamous cell carcinomas in female hemizygous Tg.AC transgenic mice.
Wyde ME; Braen AP; Hejtmancik M; Johnson JD; Toft JD; Blake JC; Cooper SD; Mahler J; Vallant M; Bucher JR; Walker NJ
Toxicol Sci; 2004 Nov; 82(1):34-45. PubMed ID: 15282402
[TBL] [Abstract][Full Text] [Related]
13. Topical application of representative multifunctional acrylates produced proliferative and inflammatory lesions in F344/N rats and B6C3F1 mice, and squamous cell neoplasms in Tg.AC mice.
Doi AM; Hailey JR; Hejtmancik M; Toft JD; Vallant M; Chhabra RS
Toxicol Pathol; 2005; 33(6):631-40. PubMed ID: 16176922
[TBL] [Abstract][Full Text] [Related]
14. A transgenic mouse model (TG.AC) for skin carcinogenesis: inducible transgene expression as a second critical event.
Hansen LA; Spalding JW; French JE; Tennant RW
Prog Clin Biol Res; 1995; 391():223-35. PubMed ID: 8532720
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of the hemizygous transgenic Tg.AC mouse for carcinogenicity testing of pharmaceuticals. II. A genotypic marker that predicts tumorigenic responsiveness.
Thompson KL; Rosenzweig BA; Sistare FD
Toxicol Pathol; 1998; 26(4):548-55. PubMed ID: 9715514
[TBL] [Abstract][Full Text] [Related]
16. Hemizygous Tg.AC transgenic mouse as a potential alternative to the two-year mouse carcinogenicity bioassay: evaluation of husbandry and housing factors.
Holden HE; Stoll RE; Spalding JW; Tennant RW
J Appl Toxicol; 1998; 18(1):19-24. PubMed ID: 9526830
[TBL] [Abstract][Full Text] [Related]
17. The Tg rasH2 mouse in cancer hazard identification.
Morton D; Alden CL; Roth AJ; Usui T
Toxicol Pathol; 2002; 30(1):139-46. PubMed ID: 11890467
[TBL] [Abstract][Full Text] [Related]
18. Chemically induced skin carcinogenesis in a transgenic mouse line (TG.AC) carrying a v-Ha-ras gene.
Spalding JW; Momma J; Elwell MR; Tennant RW
Carcinogenesis; 1993 Jul; 14(7):1335-41. PubMed ID: 8330346
[TBL] [Abstract][Full Text] [Related]
19. Oxymetholone: II. Evaluation in the Tg-AC transgenic mouse model for detection of carcinogens.
Holden HE; Stoll RE; Blanchard KT
Toxicol Pathol; 1999; 27(5):507-12. PubMed ID: 10528629
[TBL] [Abstract][Full Text] [Related]
20. Tripropylene glycol diacrylate but not ethyl acrylate induces skin tumors in a twenty-week short-term tumorigenesis study in Tg.AC (v-Ha-ras) mice.
Nylander-French LA; French JE
Toxicol Pathol; 1998; 26(4):476-83. PubMed ID: 9715506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
